Technical Analysis for BLTE - Belite Bio, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Jack-in-the-Box Bearish | Bearish Swing Setup | -3.38% | |
| Lower Bollinger Band Walk | Weakness | -3.38% | |
| Inside Day | Range Contraction | -3.38% | |
| Wide Bands | Range Expansion | -3.38% | |
| Lower Bollinger Band Touch | Weakness | -3.38% | |
| Oversold Stochastic | Weakness | -3.38% | |
| Expansion Breakdown | Bearish Swing Setup | 3.40% | |
| Lower Bollinger Band Walk | Weakness | 3.40% |
| Alert | Time |
|---|---|
| Lower Bollinger Band Support | about 6 hours ago |
| Down 5% | about 6 hours ago |
| Fell Below Lower Bollinger Band | about 6 hours ago |
| Down 3% | about 9 hours ago |
| Down 2 % | about 9 hours ago |
Get a Trading Assistant
- Earnings date: 05/08/2024
Belite Bio, Inc. Description
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Diabetes Drug Development Hepatitis Steatohepatitis Non Alcoholic Fatty Liver Disease Liver Disease Oral Therapy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 48.6 |
| 52 Week Low | 11.05 |
| Average Volume | 43,851 |
| 200-Day Moving Average | 36.33 |
| 50-Day Moving Average | 42.54 |
| 20-Day Moving Average | 38.65 |
| 10-Day Moving Average | 36.95 |
| Average True Range | 2.47 |
| RSI (14) | 32.89 |
| ADX | 41.78 |
| +DI | 8.59 |
| -DI | 33.58 |
| Chandelier Exit (Long, 3 ATRs) | 37.43 |
| Chandelier Exit (Short, 3 ATRs) | 38.43 |
| Upper Bollinger Bands | 44.83 |
| Lower Bollinger Band | 32.46 |
| Percent B (%b) | 0.08 |
| BandWidth | 32.02 |
| MACD Line | -2.28 |
| MACD Signal Line | -1.78 |
| MACD Histogram | -0.4947 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 37.24 | ||||
| Resistance 3 (R3) | 37.37 | 36.24 | 36.61 | ||
| Resistance 2 (R2) | 36.24 | 35.27 | 36.17 | 36.39 | |
| Resistance 1 (R1) | 34.83 | 34.67 | 34.27 | 34.70 | 36.18 |
| Pivot Point | 33.70 | 33.70 | 33.41 | 33.63 | 33.70 |
| Support 1 (S1) | 32.29 | 32.73 | 31.73 | 32.16 | 30.68 |
| Support 2 (S2) | 31.16 | 32.13 | 31.09 | 30.47 | |
| Support 3 (S3) | 29.75 | 31.16 | 30.26 | ||
| Support 4 (S4) | 29.62 |
